Angiotech Pharma (ANPI) CEO Hunter Buys 49.5K Shares
More News related to ANPI
- Angiotech Pharmaceuticals, Inc. announces financial results for the third quarter ended September 30, 2009
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Angiotech Pharmaceuticals announces commercial launch of the Tan Endoglide(TM) Endothelium Insertion System in the United States at the American Academy of Ophthalmology annual meeting
- Angiotech Pharmaceuticals (ANPI) Receives FDA Letter Regarding 510k Submission of Bio-Seal
- Angiotech Pharmaceuticals provides update on Bio-Seal(TM) 510(K) submission
More News related to Insider Trades
- After-Hours Movers 12/02: KTCC, PSS, SEAC, BAC Higher; SIGM, SNPS, ARO, JAS, VRTX Lower
- Trading Radar for 12/3: Marvell (MRVL), Toll Bros. (TOL), Del Monte (DLM), Smith & Wesson (SWHC) Report
- Unusual 11 Mid-Day Movers 12/02: ABCW, BIOF, GRH, STEM Higher; HEB, HDY, BGP, CBAK Lower
- Notable ETF Movers 12/2: GDX, TUR Up; UNG, USO, THD Down
- Notable Analyst Rating Changes 12/2: AMR/UAUA, RFMD, STI, SAY, KBH, BBT Upgraded; STZ, MTL, BWP, POM Downgraded
Angiotech Pharmaceutical (Nasdaq: ANPI) President and CEO, William Hunter, purchased 49,500 shares on 9/29 at prices ranging from $1.89-$1.91, bringing his stake to 5,898,091 shares.
Mr. Hunter is the largest shareholder in Angiotech.
Related Categories
Insider TradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
